Teladoc Health Inc
For the period ended May 23, 2024. Filed Apr 9, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 23, 2024 · Filed Apr 9, 2024
Contents
Summary Compensation Table
2023 summary compensation table
| Name andprincipal position · Year · Salary($) · Bonus($) · Stockawards(1)($) · Optionawards(1)($) · Non-equityincentive plancompensation(2)($) · All othercompensation($) · Total($) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jason Gorevic*Former chief executive officer | 2023 | 764,167 | — | 10,000,006 | — | 836,363 | 13,200 | (3) | 11,613,736 | ||||||
| 2022 | 695,833 | — | 10,000,020 | — | 168,000 | 12,200 | 10,876,053 | ||||||||
| 2021 | 654,167 | — | 10,000,131 | — | 972,000 | 11,600 | 11,637,898 | ||||||||
| Mala Murthy*Interim chief executive officer and principal financial officer | 2023 | 516,667 | — | 4,999,975 | — | 415,000 | 13,200 | (3) | 5,944,842 | ||||||
| 2022 | 493,333 | — | 6,799,959 | 2,399,973 | 243,800 | 12,200 | 9,949,265 | ||||||||
| 2021 | 454,167 | — | 3,249,841 | — | 415,000 | 11,600 | 4,130,608 | ||||||||
| Laizer KornwasserPresident, enterprise growth and global markets | 2023 | 500,000 | — | 4,499,980 | — | 465,000 | — | 5,464,980 | |||||||
| 2022 | 94,697 | 550,000 | (4) | 6,999,992 | — | 500,000 | — | 8,144,689 | |||||||
| Michael WatersChief operating officer | 2023 | 470,000 | — | 4,000,012 | — | 320,000 | 7,833 | (3) | 4,797,845 | ||||||
| 2022 | 205,625 | 775,000 | (4) | 5,000,013 | — | 352,500 | — | 6,333,138 | |||||||
| Adam C. VandervoortChief legal officer and secretary | 2023 | 446,667 | — | 2,849,978 | — | 226,000 | 13,200 | (3) | 3,535,845 | ||||||
| 2022 | 425,000 | — | 3,349,988 | 1,339,995 | 153,700 | 12,200 | 5,280,883 | ||||||||
| 2021 | 394,167 | — | 2,499,978 | — | 245,000 | 11,600 | 3,150,745 | ||||||||
- Ms. Murthy, who served as our Chief Financial Officer for all of fiscal 2023, became our interim Chief Executive Officer and Principal Financial Officer on April 5, 2024, replacing Mr. Gorevic.
(1)Represents the aggregate grant date fair value of awards granted during the year referenced, computed in accordance with ASC Topic 718, excluding the effect of estimated forfeitures. For additional information about these awards, please see Note 13 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 23, 2024. The maximum possible value of the PSUs granted in 2023, based on the closing price per share of our common stock on the date they were granted, was as follows:
| Name | Maximum possible value of the 2023 PSUS($) |
|---|---|
| Jason Gorevic | 9,250,026 |
| Mala Murthy | 4,624,946 |
| Laizer Kornwasser | 4,162,476 |
| Michael Waters | 3,700,005 |
| Adam C. Vandervoort | 2,636,229 |
For additional information regarding the stock-based awards granted to the named executive officers in 2023, refer to the “2023 Grants of Plan-Based Awards Table.”
(2)Amounts listed were earned under our annual cash incentive program.
(3)Represents company matching contributions to the named executive officer’s 401(k) plan account.
(4)Represents one-time signing bonus received upon commencement of employment.
| 48 | Teladoc Health | 2024 Proxy Statement |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.